US FDA grants “Emergency Use Authorization” for ePlex® SARS-CoV-2 test

The test was developed for the qualitative detection of SARS-CoV-2 virus in nasopharyngeal swab samples for patients suspected of COVID-19. The test is exclusively for use on the company’s ePlex system, which had a global installed base of more than 500 analysers worldwide.


Biospace Inc.